| HOME >> MEDICINE >> TECHNOLOGY |
5,000,0003,500,000 Proceeds from maturity of available-for-sale investments
3,200,0009,518,252 Purchases of held-to-maturity investments
(2,500,000)(7,640,000) Purchases of available-for-sale investments
(4,921,036)(3,046,270) Purchases of property, plant and equipment
(137,101)(222,826) Proceeds from sale of property, plant and equipment
7,038- Purchase of intangible assets
(4,440)(77,738)Net cash provided by investing activities
644,4612,031,418Cash flows from financing activities: Net proceeds from exercise of options
150,000208,825Net cash provided by financing activities
150,000208,825Effect of exchange rate changes on cash and cash equivalents
(6,313)(26,208)Net increase (decrease) in cash and cash equivalents
156,315(503,003)Cash and cash equivalents at beginning of period
4,653,2266,063,573Cash and cash equivalents at end of period
$4,809,541$5,560,570Cash paid during the period for interest
$12$57Cash paid during the period for income taxes
42,31931,307
Non-GAAP Financial Measures: The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2012 PR Newswire. All rights reserved |